Long-Term Assessment of Pancreatic Function After Pancreatectomy for Cystic Neoplasms.


Journal

The Journal of surgical research
ISSN: 1095-8673
Titre abrégé: J Surg Res
Pays: United States
ID NLM: 0376340

Informations de publication

Date de publication:
03 2020
Historique:
received: 24 05 2019
revised: 20 08 2019
accepted: 19 09 2019
pubmed: 20 11 2019
medline: 11 6 2020
entrez: 20 11 2019
Statut: ppublish

Résumé

With advances in cross-sectional imaging, pancreatic cysts are more frequently diagnosed and have become a common indication for pancreatectomy. The impact of pancreatectomy in these patients is important. The purpose of this study was to assess short-term outcomes, long-term nutritional status, quality of life (QOL), and pancreas function after pancreatectomy for cystic neoplasms. At a single institution, patients at least 3 y post-pancreatectomy for benign cystic neoplasms were identified. Using a validated questionnaire, short-term outcomes, long-term outcomes including endocrine and exocrine insufficiency, long-term nutritional status, and preoperative and postoperative QOL were compared based on operation and indication for resection. Among 102 eligible patients, 70 had valid contact information and 51 (72.9%) agreed to participate. Median follow-up was 6 (4-8) y. Patients undergoing pancreatoduodenectomy for benign cysts had higher morbidity than a similar cohort resected for pancreatic adenocarcinoma (patients with at least 1 ≥ grade 2 complication [49.0% versus 31.6%, P = 0.038]). After long-term follow-up, pancreatectomy did not significantly affect perceived QOL. Half of patients had mild-moderate or severe malnourishment, but pancreatic enzyme replacement was reported by only 4 (7.8%) patients. New-onset diabetes was present in 15 (29.4%) patients with median time-to-diagnosis of 6 (1-12) mo after resection. Pancreatectomy for benign cysts did not negatively impact patients' perceived QOL. However, after long-term follow-up, malnutrition and pancreatic insufficiency occurred in a significant percentage and may be greater than previously estimated. Consideration of short- and long-term outcomes should factor into preoperative counseling, especially in cysts with minimal risk of progression to malignancy.

Sections du résumé

BACKGROUND
With advances in cross-sectional imaging, pancreatic cysts are more frequently diagnosed and have become a common indication for pancreatectomy. The impact of pancreatectomy in these patients is important. The purpose of this study was to assess short-term outcomes, long-term nutritional status, quality of life (QOL), and pancreas function after pancreatectomy for cystic neoplasms.
MATERIALS AND METHODS
At a single institution, patients at least 3 y post-pancreatectomy for benign cystic neoplasms were identified. Using a validated questionnaire, short-term outcomes, long-term outcomes including endocrine and exocrine insufficiency, long-term nutritional status, and preoperative and postoperative QOL were compared based on operation and indication for resection.
RESULTS
Among 102 eligible patients, 70 had valid contact information and 51 (72.9%) agreed to participate. Median follow-up was 6 (4-8) y. Patients undergoing pancreatoduodenectomy for benign cysts had higher morbidity than a similar cohort resected for pancreatic adenocarcinoma (patients with at least 1 ≥ grade 2 complication [49.0% versus 31.6%, P = 0.038]). After long-term follow-up, pancreatectomy did not significantly affect perceived QOL. Half of patients had mild-moderate or severe malnourishment, but pancreatic enzyme replacement was reported by only 4 (7.8%) patients. New-onset diabetes was present in 15 (29.4%) patients with median time-to-diagnosis of 6 (1-12) mo after resection.
CONCLUSIONS
Pancreatectomy for benign cysts did not negatively impact patients' perceived QOL. However, after long-term follow-up, malnutrition and pancreatic insufficiency occurred in a significant percentage and may be greater than previously estimated. Consideration of short- and long-term outcomes should factor into preoperative counseling, especially in cysts with minimal risk of progression to malignancy.

Identifiants

pubmed: 31740011
pii: S0022-4804(19)30690-0
doi: 10.1016/j.jss.2019.09.045
pmc: PMC8094044
mid: NIHMS1688990
pii:
doi:

Types de publication

Comparative Study Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

547-555

Subventions

Organisme : NHLBI NIH HHS
ID : T32 HL139425
Pays : United States

Informations de copyright

Copyright © 2019. Published by Elsevier Inc.

Références

Pancreatology. 2017 Sep - Oct;17(5):738-753
pubmed: 28735806
Pancreas. 2014 Jul;43(5):755-61
pubmed: 24743379
HPB (Oxford). 2010 Sep;12(7):472-81
pubmed: 20815856
Pancreas. 2011 Nov;40(8):1258-63
pubmed: 21705943
J Am Coll Surg. 2015 Jun;220(6):1087-95
pubmed: 25868415
Pancreatology. 2017 Nov - Dec;17(6):974-982
pubmed: 28958898
Pancreas. 2016 Aug;45(7):986-91
pubmed: 26692445
Surgery. 2018 Nov;164(5):1035-1048
pubmed: 30029989
Ann Surg. 2006 May;243(5):673-80; discussion 680-3
pubmed: 16633003
Dig Dis Sci. 2017 Mar;62(3):626-632
pubmed: 28116593
AJR Am J Roentgenol. 2008 Sep;191(3):802-7
pubmed: 18716113
Ann Surg. 2017 Oct;266(4):685-692
pubmed: 28657944
Med Care. 2009 Aug;47(8):866-74
pubmed: 19584761
Ann Surg. 2009 Aug;250(2):177-86
pubmed: 19638919
Ann Surg. 2013 Dec;258(6):930-42
pubmed: 23732268
Nutr Clin Pract. 2008 Aug-Sep;23(4):405-9
pubmed: 18682592
Surgery. 2017 Mar;161(3):584-591
pubmed: 28040257
Pancreatology. 2014 Mar-Apr;14(2):131-6
pubmed: 24650968
Surgery. 2007 Nov;142(5):761-8
pubmed: 17981197
J Surg Oncol. 2017 Feb;115(2):144-150
pubmed: 27859270
Ann Surg. 2000 Jun;231(6):890-8
pubmed: 10816633
Isr Med Assoc J. 2011 May;13(5):284-9
pubmed: 21845969
Surgery. 2005 Jul;138(1):8-13
pubmed: 16003309
Pancreatology. 2009;9(6):729-37
pubmed: 20090394
JMIR Ment Health. 2017 Sep 26;4(3):e37
pubmed: 28951382
J Clin Oncol. 2002 May 1;20(9):2229-39
pubmed: 11980994
Br J Surg. 2008 Jan;95(1):85-91
pubmed: 18041022
J Gastrointest Surg. 2014 Jan;18(1):172-79; discussion 179-80
pubmed: 24002771
Ann Surg. 2018 Feb;267(2):259-270
pubmed: 28834847
Surg Infect (Larchmt). 2015 Dec;16(6):657-68
pubmed: 26244748
J Surg Oncol. 2013 Jan;107(1):97-103
pubmed: 22991309
Int J Surg. 2011;9(8):655-8
pubmed: 21925294
Pancreatology. 2012 May-Jun;12(3):183-97
pubmed: 22687371
BMC Surg. 2015 Oct 30;15:120
pubmed: 26518473
Nutrients. 2017 Mar 07;9(3):
pubmed: 28272344
J Am Coll Surg. 2013 Jan;216(1):1-14
pubmed: 23122535
Br J Surg. 2016 Feb;103(3):257-66
pubmed: 26785646
Pancreatology. 2006;6(1-2):17-32
pubmed: 16327281

Auteurs

Kevin P Shah (KP)

Michael E DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas.

Katherine A Baugh (KA)

Michael E DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas.

Lisa S Brubaker (LS)

Michael E DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas.

George Van Buren (G)

Michael E DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas.

Nicole Villafane-Ferriol (N)

Michael E DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas.

Amy L McElhany (AL)

Michael E DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas.

Sadde Mohamed (S)

Michael E DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas.

Eric J Silberfein (EJ)

Michael E DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas.

Cary Hsu (C)

Michael E DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas.

Nader N Massarweh (NN)

Michael E DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas.

Hop S Tran Cao (HS)

Michael E DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas.

Jose E Mendez-Reyes (JE)

Michael E DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas.

William E Fisher (WE)

Michael E DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas. Electronic address: wfisher@bcm.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH